Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Deciding on treatment in multiple sclerosis].

V M Rivera1

  • 1Department of Neurology Baylor College of Medicine. 6560 Fannin, Suite 1224, Houston, Texas, 77030, USA. vrivera@bcm.tmc.edu

Revista De Neurologia
|February 11, 2003
PubMed
Summary

Recent advancements in multiple sclerosis treatment involve evidence-based disease-modifying medications, including immunomodulation and immunosuppression, guided by clinical trials and MRI outcomes for personalized patient care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Therapeutic attitudes towards multiple sclerosis in Central America and the Caribbean facing the SARS-CoV-2 pandemia].

Neurologia·2020
Same author

Multiple sclerosis as a universal disease and the challenges to immigrants in high prevalence countries.

European journal of neurology·2018
Same author

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

The New England journal of medicine·2013
Same author

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Evaluation of a rapamycin-regulated serotype 2 adeno-associated viral vector in macaque parotid glands.

Oral diseases·2010
Same author

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.

Annals of oncology : official journal of the European Society for Medical Oncology·2009

Area of Science:

  • Neurology
  • Clinical Trials
  • Medical Imaging

Context:

  • Multiple sclerosis (MS) treatment has evolved significantly.
  • Recent years have seen a shift towards evidence-based practices.

Purpose:

  • To summarize modern treatment strategies for multiple sclerosis.
  • To highlight the role of clinical trials and advanced techniques in guiding treatment decisions.

Summary:

  • Controlled clinical trials now incorporate Magnetic Resonance Imaging (MRI) and statistical analysis for measurable outcomes.
  • Disease-modifying medications, such as interferons and glatiramer acetate for relapsing-remitting MS, and combination therapies or immunosuppression for progressive forms, are key.
  • Evidence from these studies informs clinicians on selecting optimal treatments for individual patients.

Impact:

  • Provides clinicians with data-driven guidance for personalized multiple sclerosis management.
  • Enhances treatment efficacy through the application of advanced diagnostic and therapeutic approaches.
  • Contributes to improved patient outcomes in multiple sclerosis care.

Related Experiment Videos